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Despite the effective clinical use of steroids for the treatment of Diamond Blackfan anemia (DBA), the mechanisms through
which glucocorticoids regulate human erythropoiesis remain poorly understood. We report that the sensitivity of erythroid
differentiation to dexamethasone is dependent on the developmental origin of human CD34+ progenitor cells, specifically
increasing the expansion of CD34+ progenitors from peripheral blood (PB) but not cord blood (CB). Dexamethasone
treatment of erythroid-differentiated PB, but not CB, CD34+ progenitors resulted in the expansion of a newly defined
CD34+CD36+CD71hiCD105med immature colony-forming unit–erythroid (CFU-E) population. Furthermore, proteomics analyses
revealed the induction of distinct proteins in dexamethasone-treated PB and CB erythroid progenitors. Dexamethasone
treatment of PB progenitors resulted in the specific upregulation of p57Kip2, a Cip/Kip cyclin–dependent kinase inhibitor, and
we identified this induction as critical; shRNA-mediated downregulation of p57Kip2, but not the related p27Kip1, significantly
attenuated the impact of dexamethasone on erythroid differentiation and inhibited the expansion of the immature CFU-E
subset. Notably, in the context of DBA, we found that steroid resistance was associated with dysregulated p57Kip2 expression.
Altogether, these data identify a unique glucocorticoid-responsive human erythroid progenitor and provide new insights into
glucocorticoid-based therapeutic strategies for the treatment of patients with DBA.

Introduction

Diamond Blackfan anemia (DBA) is an inherited bone marrow
(BM) failure syndrome with an incidence of 5 to 10 cases per million live births and is characterized by red cell aplasia, a range
of physical anomalies, developmental bone defects, and cancer
predisposition (1, 2). More than 70% of the patients diagnosed
with DBA have defects in ribosome biogenesis due to mutations
in genes encoding ribosomal proteins. In addition, mutations in
the GATA1 transcription factor, a key regulator of erythroid development, and TSR2, a pre-rRNA processing protein, have recently
been identified in several families with DBA (3, 4). The genetic
landscape of DBA is heterogeneous, but genotype and phenotype
correlations have been noted in association with mutations in the
RPL5 and RPL11 ribosomal proteins in patients (5).
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The standard of care for patients with DBA after the first year
of life is glucocorticoids. Notably, a majority of treated patients
have an increase in red cell production and have a reduced dependency on blood transfusions (6–8). However, the therapeutic dose
is extremely variable among patients, and many become refractory to treatment over time. Once patients are glucocorticoid
refractory they become dependent on chronic RBC transfusions
unless they enter remission or undergo curative hematopoietic
stem cell transplantation (7). The actions of glucocorticoids have
been well studied in many disease contexts. These molecules
interact with the glucocorticoid receptor (GR), leading to nuclear
translocation of the resulting complex, which binds DNA at glucocorticoid response elements (GREs) and ultimately activates gene
transcription (9). However, the specific mechanisms of action of
glucocorticoids in the erythroid system in both healthy individuals
and patients with DBA remain to be fully elucidated. Several studies have demonstrated that glucocorticoids act at the erythroid
progenitor level, but the precise stages of erythroid differentiation
at which they exert their effects have not been identified (10–13).
This is due in part to the considerable heterogeneity of erythroid
progenitor populations and the different markers and model sysjci.org   Volume 130   Number 4   April 2020
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tems that are used for studying glucocorticoid effects on erythropoiesis. Indeed, early burst-forming unit–erythroid (BFU-E) and
colony-forming unit–erythroid (CFU-E) progenitors are often
characterized on the basis of their functional ability to form erythroid colonies in colony-forming assays (CFAs), and immunophenotypic evaluations (14–18) are still in progress.
A further difficulty in evaluating the impact of glucocorticoids
on BFU-E and CFU-E progenitors is due to important differences
in murine versus human erythroid differentiation. In mice, the
vast majority of research has focused on fetal liver progenitors,
with a detailed characterization of early and late populations of
fetal liver BFU-Es (19–21). Although several studies performed
on murine fetal liver cells have suggested that dexamethasone
acts at the BFU-E stage (11, 13, 19), a more recent study showed
that dexamethasone enhances the maintenance of proliferative
murine CFU-Es by upregulating p57Kip2, a member of the Cip/Kip
cyclin–dependent kinase (CDK) inhibitor (CKI) protein family
(10). Under these conditions, the proliferative CFU-E population
is maintained, and there is a delayed differentiation to the less proliferative proerythroblast (pro-EB) stage. However, it is not clear
whether these data in fetal murine erythroid progenitors translate
to humans, as regards both the potential ex vivo heterogeneity of
BFU-E and CFU-E populations and, more important, the diversity of erythroid progenitor subpopulations in human BM. These
limitations have made it challenging to elucidate the mechanisms
through which glucocorticoids act at different stages of erythroid
progenitor development, under both physiological and patho
logical conditions.
In the present study, we identified significant differences in
the potential of dexamethasone to affect physiological as well as
disordered human erythropoiesis. In the context of physiological differentiation, we found that, although it affected terminal
erythropoiesis independently of the source, dexamethasone had
an effect on the expansion of CD34+ hematopoietic stem and progenitor cells (HSPCs) isolated from adult peripheral blood (PB),
but not from cord blood (CB). Dexamethasone did not affect
BFU-Es, but using a new set of cell-surface markers, we identified
a unique, PB progenitor–generated subset of transitional CD34+
CD36+CD71hiCD105med CFU-Es that were dexamethasone responsive. Mass spectrometry–based quantitative proteomics analyses
revealed substantial differences in the effects of dexamethasone
on PB and CB progenitors, with upregulation of nuclear receptor
subfamily 4 group A member 1 (NR4A1), a negative cell-cycle regulator (22), in the former cell type. Furthermore, we found that the
p57Kip2 Cip/Kip CKI was specifically upregulated by dexamethasone in PB-derived CFU-Es and that its downregulation significantly attenuated the effects of this glucocorticoid. Even more
notably, we found that p57Kip2 was not upregulated by dexamethasone in CFU-Es isolated from steroid-resistant patients with DBA.
These findings open new avenues for the development of specific
therapeutic strategies for these patients.

Results

Dexamethasone increases the proliferation of adult human CFU-Es. It
has previously been shown that dexamethasone increases the proliferation of erythroid progenitors derived from both healthy and
DBA HSPCs (23–25). However, the differentiation stage at which
2098
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dexamethasone exerts its effects is still unclear. Using a serumfree expansion medium that allowed for the effective erythroid
differentiation of HSPCs under steady-state conditions (without
dexamethasone), we studied the effects of dexamethasone on
human erythropoiesis (18, 26). Notably, we found that dexamethasone (100 nM) increased the expansion of CD34+ cells isolated
from adult PB by 7-fold as compared with control conditions
(Figure 1A). Surprisingly, though, we did not detect a dexamethasone-mediated increase in the expansion of CB-derived CD34+
cells. In fact, total numbers of precursors differentiating from
CB CD34+ cells were approximately 4-fold lower in the presence
versus absence of dexamethasone (Figure 1A), strongly suggesting marked developmental differences in the responsiveness of
human PB and CB progenitors to this glucocorticoid.
To further elucidate the erythroid differentiation stage at
which dexamethasone acts, we used our recently developed
experimental strategy for the characterization of BFU-E and
CFU-E progenitors, based on surface expression levels of glycophorin A (GPA), IL-3R, CD34, and CD36. The absolute numbers
of BFU-Es and CFU-Es generated from 106 PB and CB CD34+
cells were enumerated on the basis of cell-surface marker expression in the absence and presence of dexamethasone (Figure 1B).
Beginning on day 7, the number of BFU-Es (defined as GPA–IL3R–
CD34+CD36 –) cells decreased in cultures starting with PB as well
as CB CD34+ progenitors, in the absence and presence of dexamethasone, and the extent of this decrease was enhanced by dexamethasone. In marked contrast, the absolute number of CFU-Es
(defined as GPA–IL3R–CD34–CD36+) increased over time, and
this increase was more pronounced in dexamethasone-treated
adult PB CD34+ cells. Notably, dexamethasone decreased the
appearance of terminally differentiated GPA+ cells in both PBand CB-derived cultures. These data indicate that erythroblasts
from both sources were responsive to this glucocorticoid, resulting in a delayed transition to terminal erythroid differentiation
(Supplemental Figure 1, A and B). However, cells derived from PB
were more affected, possibly because of additional effects at the
progenitor levels and at this transitional stage. We also detected
this decrease in terminal erythroid differentiation as a function of
α4-integrin/band 3 profiles as well as reduced hemoglobinization
(Supplemental Figure 1A).
To further validate that the CFU-E was the population primarily responding to dexamethasone, we sorted CFU-Es derived
from PB and CB cultures of CD34+ cells and studied their potential for expansion in serum-free expansion media. As shown in
Figure 1C, the expansion of CFU-Es purified from adult CD34+
cells increased by 5-fold in the presence of dexamethasone. Once
again, dexamethasone had little to no effect on the proliferation
of purified CFU-Es derived from CB, supporting the idea that the
response to dexamethasone is linked to the specific developmental stage of erythroid progenitors. We performed the same experiments using increasing concentrations of dexamethasone on
sorted populations of erythroid progenitors derived from adult PB
cultures and observed that the effect on proliferation was maximal
at the 100-nM dose (Supplemental Figure 2).
Functional assays using methylcellulose cultures with erythropoietin (Epo) only, a culture condition that supports the growth
of CFU-Es but not BFU-Es (requiring both stem cell factor [SCF]
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Figure 1. Dexamethasone enhances the proliferation of human CFU-Es derived from PB
CD34+ cells. (A) Fold change in total expansion of PB-derived (red) and CB-derived (black,
n = 5) CD34+ cells upon erythroid differentiation in the presence or absence of dexamethasone for 14 days. Data represent the mean ± SEM. (B) Total numbers of BFU-Es and CFU-Es
generated from PB and CB cultures in the absence (PB–, CB–) or presence (PB+, CB+) of
dexamethasone. Data are representative of 1 of 3 independent experiments. (C) Fold change
in purified CFU-Es derived from PB (n = 6) and CB (n = 4) in the presence of dexamethasone
relative to untreated controls after 14 days of expansion. Data represent the mean ± SEM.
(D) Average size (area) of colonies generated from purified CFU-Es derived from untreated PB
and CB after 5 days of culture in the absence (open circles) or presence (solid circles) of dexamethasone (n = 3). Data represent the mean ± SEM. Dex, dexamethasone. (E) Percentages of
reticulocytes in 3 patients with DBA following treatment with prednisone, beginning on day
0. *P < 0.05, by 2-tailed Student’s t test (A, C, and D).
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and Epo [ref. 18]), revealed that treatment with dexamethasone
markedly increased the colony size of PB-derived CFU-Es but had
very little or no effect on CB-derived CFU-E colony size (Figure
1D and Supplemental Figure 3), despite the fact that in the absence
of dexamethasone the colony size of purified CB-derived CFU-Es
was larger than that generated by PB-derived CFU-Es. Taken
together, these data imply that only human CFU-Es derived from
adult PB respond to dexamethasone by increasing proliferation.
Previous studies have shown that it takes at least 2 weeks in
vivo for healthy BM to produce reticulocytes from the BFU-E stage
and approximately 7 to 10 days from the CFU-E stage (27–29). We
hypothesized that if the CFU-E is the progenitor population that
responds to glucocorticoids in vivo, then patients treated with
steroids should present with reticulocytosis in less than 2 weeks.
We followed patients with DBA over a 1-month period before and
after treatment with prednisone. We observed that in each patient,
the reticulocyte count increased within 7 to 11 days after initiation
of the treatment, strongly suggesting that in vivo, the CFU-E is
indeed the glucocorticoid-responsive population (Figure 1E). We
further noticed a decline in the reticulocyte response in a similar
time frame, in association with a decrease in the dose of prednisone administered to the patient. Our finding that patients with
DBA develop reticulocytosis within less than 2 weeks of starting
prednisone treatment strongly suggests the presence of a mature,
steroid-responsive progenitor, such as a CFU-E.
Dexamethasone targets a subpopulation of adult-derived CFU-Es.
We previously described that, given the surface expression of CD34
and CD36, we could obtain a highly enriched population of BFU-Es
(GPA–IL-3R–CD34+CD36–) and CFU-Es (GPA–IL-3R–CD34–CD36+)
(18). More recently, we reported a transitional progenitor population defined as GPA–IL-3R–CD34+CD36+, which is more predominant during differentiation of adult PB than that of CB (30). Notably, the kinetics of progression through these differentiation states
were also altered with dexamethasone treatment (Figure 2A).
Having identified 2 phenotypically different CFU-E populations (CD34+CD36+ and CD34–CD36+), we sought to determine
whether there were additional cell-surface markers that would
provide further insights into the heterogeneity of these CFU-E
populations. We focused on CD71, the transferrin receptor, and
CD105 (endoglin), both of which demonstrated large differences
in their RNA expression during erythroid differentiation at the
progenitor stages (Supplemental Figure 4A).
On the basis of the expression patterns of CD71 and CD105
on CD34+CD36+ cells, we identified a continuum of cells with 2
distinct populations: CD71hiCD105med and CD71hiCD105hi (Figure 2B). We then sorted these different cell populations and performed colony-forming assays in the presence of either Epo alone,
to produce colonies with the traditional definition of a CFU-E, or
in complete medium with SCF, Epo, IL-3, IL-6, granulocyte CSF
(G-CSF), and granulocyte-macrophage–CSF (GM-CSF). Interestingly, although both sorted populations from CD34+CD36+ cells
generated colonies in the presence of Epo only (Figure 2C), only
CD71hi CD105med cells showed marked responsiveness to SCF in
complete medium, whereas SCF had little or no effect on CD71hi
CD105hi cells (Figure 2C). CD71hiCD105hi cells from CD34+CD36+
cell populations responded similarly to CD3–CD36+ cell populations, with a minimal response to SCF. Given these findings, we
2100
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propose that CD71hiCD105med cells should be termed immature
CFU-Es and CD71hiCD105hi cells mature CFU-Es. Importantly,
immature CFU-Es functionally responded to dexamethasone by
increasing their colony size in a methylcellulose culture system
(Figure 2D). In marked contrast, mature CFU-Es responded marginally to dexamethasone in the same functional colony-forming
assays, and this increase was not statistically significant. When
treated with dexamethasone, PB-derived CD34+ cells preferentially maintained this immature CFU-E population. Indeed,
although both untreated and treated cells expressed comparable
levels of CD71 on their surface, approximately 50% of the PB cells
treated with dexamethasone were still CD105med compared with
untreated controls, approximately 30% of which were CD105med
by day 4 (Figure 2, E and F, left). Consequentially, the population
of CD105hi cells was decreased in PB cells treated with dexamethasone (Figure 2F, right). Taken together, these data demonstrate
that in human erythropoiesis, dexamethasone treatment preferentially maintains the immature CFU-E progenitor population for
an extended period to increase the proliferative capacity of this
cell population.
Proteomics studies highlight previously unidentified erythroid
dexamethasone targets. To begin exploring the mechanisms regulating the differential impact of dexamethasone on PB- and
CB-derived progenitors, we elected to use a global, comparative
proteomics approach. PB- and CB-derived CD34+ cells were cultured in vitro for 5 days to allow for the acquisition of sufficient
numbers of flow-sorted purified CFU-Es (~20 × 106 cells) and then
subjected to proteomics evaluation. We treated biological triplicates of PB- and CB-derived CFU-Es in the absence or presence
of dexamethasone (100 nM) for 24 hours. These cells were then
processed for proteomics analysis by liquid chromatography–
tandem mass spectrometry (LC-MS/MS). Proteomics quantified
10,045 proteins in PB samples and 10,028 proteins in CB samples (Supplemental Table 1). Proteomic evaluation of PB and CB
samples was performed in 2 separate tandem mass tag–6 (TMT-6)
plexes. This allowed for precise measurements of changes in
protein abundance due to drug treatment in the PB-plex and the
CB-plex, but less precise comparisons between PB and CB plexes.
Therefore, the observed differences between PB and CB samples
were subsequently validated in follow-up experiments.
Importantly, both PB- and CB-derived CFU-Es responded to
dexamethasone as demonstrated by the upregulation of the gene
for period 1 (PER1) (Figure 3, A and B), a major component of the
mammalian circadian clock that has long been known to be regulated by glucocorticoids (31, 32). Notably, however, the majority
of dexamethasone-upregulated proteins in PB- and CB-derived
CFU-Es differed (Figure 3, C and D), consistent with the distinct
phenotypic responses of these CFU-Es. One of the proteins whose
abundance was upregulated by dexamethasone in PB-derived
CFU-Es, but not CB-derived CFU-Es, was NR4A1 (Figure 3, C and
D), a negative cell-cycle regulator. NR4A1 is an interesting target,
given its role as a regulator of the cell cycle (22) and of T cell differentiation (33). NR4A1 also binds to HIF1α (34), an important regulator of erythroid differentiation (35). Identification of NR4A1 as a
target of dexamethasone was confirmed by Western blot analysis
(Figure 3E). Interestingly, the transcription profiles of NR4A1 as
well as of 2 other cell-cycle inhibitors, p27Kip1 and p57Kip2, showed a
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Figure 2. Dexamethasone specifically targets a transitional subpopulation of human CFU-Es derived from PB CD34+ cells. (A) PB-derived CD34+ cells
differentiated in the presence or absence of dexamethasone were evaluated as a function of their CD36 and CD34 expression profiles. Representative
plots on day 4 of differentiation are presented. Data shown are representative of 1 of 3 independent experiments. (B) Gating strategy to define mature
and immature transitional CFU-E progenitor populations based on the CD71/CD105 profiles of the CD34+CD36+ subset. Data are representative of 1 of 3
independent experiments. (C) Representative images of colonies formed by immature and mature CFU-Es as defined in B, in the presence of Epo alone or
Epo, SCF, IL-3, IL-6, G-CSF, and GM-CSF (n = 3). Scale bars: 1 mm. (D) Colony size (area) generated by immature (red) and mature (black) CFU-Es, defined as
in B and formed in the presence of Epo alone, in the absence (open circles) or presence (solid circles) of dexamethasone (n = 3). Data represent the mean
± SEM. (E) Representative histograms show CD71 and CD105 expression in PB-derived CD34+ cells differentiated in the absence (black) or presence (red) of
dexamethasone (unsorted, day 4). Percentages of CD71med and CD105med are shown in the upper left quadrant of each plot. Data are representative of 1 of 3
independent experiments. (F) Quantification of CD105med and CD105hi cells following differentiation of PB-derived CD34+ cells in the absence (control, open
circles) or presence (solid circles) of dexamethasone (day 4, n = 5). Data represent the mean ± SEM. *P < 0.05, by 2-tailed Student’s t test (D and F).
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Figure 3. Proteomics studies highlight
NR4A1 as a dexamethasone target in
erythroid-differentiated PB progenitors. (A) Ranked average log foldchange plots of differences in protein
expression induced by dexamethasone
in erythroid-differentiated PB progenitors. (B) Ranked average log foldchange plots of differences in protein
expression induced by dexamethasone
in erythroid-differentiated CB progenitors. (C) Top-20 proteins upregulated by
dexamethasone in erythroid-differentiated PB progenitors based on the log
fold change (log FC). (D) Top-20 proteins
upregulated by dexamethasone in
erythroid-differentiated CB progenitors
based on the log fold change. (E) NR4A1
expression levels in purified PB- and
CB-derived unsorted progenitors were
evaluated by Western blotting on day 4
of expansion. Expression of NR4A1 relative to GAPDH is quantified below each
lane. Data are representative of 1 of 3
independent experiments. (F) ssGSEA
of proteins differentially regulated by
dexamethasone. The top-10 upregulated and downregulated pathways
between all samples are listed, and
redundant pathways were eliminated.
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Figure 4. Dexamethasone increases p57Kip2 expression in Epo-induced PB CD34+ cells. (A) Expression of p57Kip2 and p27Kip1 was evaluated by Western blotting in CD34+ progenitors during Epo-induced erythroid differentiation. Erythroid differentiation was controlled by evaluating α-globin expression. Data are
representative of 5 independent experiments. (B) Quantification of the differences in p57Kip2 protein levels in PB and CB cultures between days 4 and 7 of
erythroid differentiation (n = 5; values for day 4 were arbitrarily set at 1.). (C) Expression of p57Kip2, p27Kip1, and GAPDH in PB-derived and CB-derived progenitors was evaluated in sorted CFU-Es following 4 days of Epo-induced differentiation in the absence (–) or presence (+) of dexamethasone. Representative
Western blots from 1 of 3 independent experiments are shown. (D) Quantification of the fold changes in p57Kip2 and p27Kip1 expression in purified PBderived (n = 7, red circles) and CB-derived (n = 6, black circles) CFU-Es in the presence of dexamethasone relative to control conditions (arbitrarily set at 1).
Data represent the mean ± SEM. (E) Quantification of the percentages of PB-derived BFU-Es, immature CFU-Es, and mature CFU-Es that were in S phase
in the absence (open circles) and presence (solid circles) of dexamethasone. S phase was quantified by Hoechst 33342 staining (n = 5). Data represent the
mean ± SEM. *P < 0.05, by 2-tailed Student’s t test (D and E).

substantial decrease between the CD34+ and BFU-E stages (Supplemental Figure 4B). Although we did not detect p57Kip2 in the
proteomics screen, it is notable that only p57Kip2 was expressed at
markedly higher levels in PB than in CB CD34+ progenitors (Supplemental Figure 4B). We also performed single-sample gene
set enrichment analysis (ssGSEA) to identify the pathways most
differentially affected by dexamethasone treatment in both PB
and CB samples (Figure 3F). Notably, we observed an increase in
proteins involved in the cell cycle and RNA processing as well as a
decrease in proteins implicated in oxidative phosphorylation and
biosynthetic pathways. Together, these data point to potential differences in the roles of cell-cycle inhibitors in CD34+ progenitors
as a function of their developmental origin.
Dexamethasone increases p57Kip2 expression in human CFU-Es.
The data presented above, together with an elegant previous study
showing that p57Kip2 regulates steroid responsiveness in murine

erythroid progenitors (10), suggested that dexamethasone would
act through p57Kip2 in PB-derived erythroid progenitors. We first
evaluated the expression levels of p57Kip2 protein as a function
of erythroid differentiation from PB and CB CD34+ cells (Figure
4A). Although p57Kip2 was expressed in early erythroid progenitors
derived from both PB and CB CD34+ cells (unsorted, day 4), the
loss of p57Kip2 was substantially more rapid in the CB cells. p57Kip2
levels in PB erythroid progenitors were reduced by 77% by day 7,
whereas expression persisted in CB progenitors (Figure 4, A and
B). Conversely, p27Kip1, a related Cip/Kip family member, was
expressed at minimal levels during early differentiation, but its
expression increased dramatically in terminally differentiating
erythroblasts (Figure 4A). These distinct expression profiles are in
agreement with previous studies showing that p57Kip2 is associated
with the quiescence of stem and progenitor cells, whereas p27Kip1
plays a role in the cell-cycle exit that occurs during terminal erythjci.org   Volume 130   Number 4   April 2020
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Figure 5. Aberrant steroid-mediated induction of p57Kip2 in erythroid
progenitors from transfusion-dependent patients with DBA. (A) The
expansion of CD34+ cells derived from healthy controls (Ctrl) (black,
n = 8), transfusion-dependent (TD) patients with DBA (blue, n = 5), and
steroid-responsive (SR) patients with DBA (red, n = 3) is presented following a 7-day stimulation. Data represent the mean ± SEM. (B) Expression
of p57Kip2 and p27Kip1 in erythroid progenitors from healthy controls and
patients with DBA, either transfusion dependent or steroid responsive,
was evaluated by Western blotting on day 7 of differentiation. Expression
of p57Kip2 relative to GAPDH is quantified below each lane, with control
levels in the healthy donor arbitrarily set at 1. (C) Quantification of the fold
change in dexamethasone-induced p57Kip2 expression following expansion
of CD34+ cells from healthy controls (n = 8) as compared with transfusiondependent patients with DBA (n = 5) and steroid-responsive patients with
DBA (n = 3). Data represent the mean ± SEM. *P < 0.05, by KruskalWallis test with Dunn’s post hoc analysis with corrections for multiple
comparisons (A and C).

roid differentiation (36, 37). Notably, however, differences in the
kinetics of p57Kip2 downregulation in CB and PB erythroid progenitors have not thus far been appreciated.
Given these findings, it was of interest to assess whether
p57Kip2 levels would be differentially affected by dexamethasone
in purified PB-derived and CB-derived progenitors. To this end,
progenitors derived from both sources were treated with dexamethasone, and the expression of p57Kip2 was quantified by West2104

jci.org   Volume 130   Number 4   April 2020

ern blotting. We evaluated total CFU-Es, because the numbers of
immature CFU-Es were insufficient in the absence of dexamethasone, particularly in CB cultures, in which the kinetics of differentiation is increased (30). Notably, within CFU-Es, we found that
p57Kip2 protein levels were increased by 1.8-fold in PB-derived progenitors but remained unchanged in CB-derived progenitors (P
< 0.05; Figure 4, C and D). These data are even more striking in
light of the finding that p27Kip1 levels were not significantly altered
in progenitors derived from either PB or CB sources (Figure 4, C
and D). Altogether, these data strongly suggest a role for p57Kip2 in
mediating the dexamethasone-induced changes in PB-derived,
but not CB-derived, progenitors.
Given that p57Kip2 is a regulator of the cell cycle, we inhibited
the transition from the G1 to the S phase (38) to determine whether
dexamethasone-mediated changes in p57Kip2 are associated with
differences in the cell-cycle dynamics of PB erythroid progenitors.
We found that the percentages of progenitors in the S phase of the
cell cycle increased significantly between the BFU-E and CFU-E
stages, from a mean of 35% to 48% (P < 0.05; Figure 4E). Notably however, dexamethasone significantly decreased S-phase
cells in immature CFU-Es, but not in the BFU-Es or mature
CFU-E subsets (Figure 4E and Supplemental Figure 5). In addition, the percentages of cells in the non–S phase of the cell cycle
were increased in immature CFU-Es (Supplemental Figure 5B).
Thus, in agreement with our data showing that the immature PBderived CFU-E subset preferentially undergoes a dexamethasonemediated expansion (Figure 2), only this subset responded to
upregulated p57Kip2 levels with a significant decrease in the number of cells in the S phase. Despite this reduction of cells in the S
phase, immature CFU-Es continued to divide, with increases in
G2/M, before further differentiating into mature CFU-Es and then
proerythroblasts and resulting in increased expansion.
p57Kip2 expression is altered in erythroid progenitors from transfusion-dependent patients with DBA. We further hypothesized that the
resistance of patients with DBA to glucocorticoids is mediated, at
least in part, by p57Kip2. To test this hypothesis, we compared dexamethasone-induced changes in p57Kip2 levels in unsorted cells on
day 7 of culture in response to dexamethasone in CD34+ cells from
healthy controls and transfusion-dependent patients with DBA.
Given the strong reduction in growth of cells from transfusion-
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Figure 6. Downregulation of CDKN1C (p57Kip2) in CD34+ progenitors attenuates the impact of dexamethasone, accelerating erythroid differentiation,
whereas olomoucine, a CKI, mimics the effect of dexamethasone. (A) CD34+ progenitors were transduced with a lentiviral vector harboring an shRNA
targeting luciferase (shLuc) or p57Kip2 (shp57). Expression of p57Kip2 was evaluated by Western blotting relative to GAPDH levels on day 7 after transduction. Data are representative of 1 of 3 independent experiments. (B) Expansion of control (shLuc) and p57Kip2-downregulated (shp57) PB CD34+ cells was
evaluated in the absence (open circles) or presence (solid circles) of dexamethasone after 14 days of culture (n = 5). Data represent the mean ± SEM. *P <
0.05, by 2-tailed Student’s t test. (C) Representative histograms of GPA expression in control (shLuc) and p57Kip2-downregulated (shp57) progenitors on day
14 of differentiation. MFIs are indicated. Data are representative of 1 of 3 independent experiments. (D) Quantification of the ratio of immature CFU-Es
to mature CFU-Es following expansion of PB-derived CD34+ cells in the absence (black circles) or presence of 100 nM dexamethasone (red circles) or 1 μM
olomoucine (blue circles) on day 4 of culture. n = 5. Data represent the mean ± SEM. *P < 0.05, by Kruskal-Wallis test with Dunn’s post hoc analysis with
corrections for multiple comparisons.

dependent patients with DBA, we evaluated p57Kip2 levels in
unsorted progenitors on day 7 of expansion (Figure 5A). Importantly, p57Kip2 levels, which were increased in healthy controls and
steroid-responsive patients with DBA in response to dexamethasone, were not affected in transfusion-dependent patients with
DBA (Figure 5, B and C). As expected from the data presented in
Figure 4C, p27Kip1 levels were not affected by dexamethasone, but
it is notable that they were dysregulated and pointedly higher or
lower in samples from patients with DBA, probably due to early
differentiation or defective terminal erythroid differentiation,
respectively, in these unsorted cells. Most critically, p57Kip2 levels
in progenitors derived from steroid-responsive patients with DBA
were upregulated in response to dexamethasone, similar to what
was observed in healthy controls (Figure 5, B and C). Notably, the
expansion of PB-derived CD34+ cells from healthy controls and
steroid-responsive patients with DBA was similar after 7 days of
culture, whereas cells from transfusion-dependent patients with
DBA showed significantly less expansion (Figure 5A). Taken
together, these results suggest a critical role for p57Kip2-associated
cell-cycle changes in the steroid responsiveness of both physiological and pathological human erythropoiesis.
Dexamethasone responsiveness is mediated by CDK activity.
In order to directly assess the role of p57Kip2 in mediating dexamethasone effects on erythroid progenitors, we used a lentivirusmediated shRNA approach to induce downregulation of p57Kip2
levels. Following transduction, p57Kip2 was downregulated by
80% as compared with cells transduced with a control luciferase–
targeting shRNA construct (Figure 6A). Notably, p57Kip2 downregulation abrogated the ability of PB-derived CD34+ cells to respond
to dexamethasone, monitored as a function of their expansion
(Figure 6B). Moreover, we observed that erythroid differentiation
was accelerated, as demonstrated by 1.5- and 3-fold increases in
GPA expression levels in control- and dexamethasone-treated

progenitors, respectively (Figure 6C). Finally, this effect on erythroid progenitors was specific to the p57Kip2 CKI, as downregulation
of p27Kip1 did not alter the expansion of these progenitors (Supplemental Figure 6, A and B). The effect on p27Kip1 was only noticed
at later stages and was indicated by a delay in terminal differentiation measured by the surface markers α4-integrin and band3
(Supplemental Figure 6C). Altogether, these data reveal the function of p57Kip2 in regulating the balance between human erythroid
progenitor proliferation and differentiation and, furthermore, in
controlling glucocorticoid responsiveness under both physiological and pathological conditions.
Given our finding that an increase in levels of p57Kip2, a CKI, is
critical for dexamethasone responsiveness, we hypothesized that
inhibiting cyclin kinases would have the same effect as increasing
p57Kip2. Notably, treatment of PB-derived CD34+ cells with olomoucine (1 μM), a small-molecule CDK1 and CDK2 inhibitor (39),
resulted in a significant increase in the ratio of immature CFU-Es/
mature CFU-Es to levels similar to those induced by dexamethasone (Figure 6D). Together, these data demonstrate the importance of CDK/CKI balance in the expansion of the immature
CFU-E population.
Dexamethasone upregulates p57Kip2 expression in erythroid progenitors derived from human BM. To assess the effects of dexamethasone on populations of cells that are directly targeted by the drug
in vivo, we repeated key experiments with erythroid progenitors
derived from human BM. In culture with serum-free expansion
media, we found that the expansion of BM-derived CD34+ cells
increased significantly in the presence of dexamethasone (Figure
7A). When examining the expression of CD105 in BM-derived
progenitors, we observed that dexamethasone treatment maintained the population of CD105med cells and correspondingly
decreased the population of CD105hi cells (Figure 7B). Furthermore, treatment of BM-derived CFU-Es with dexamethasone
jci.org   Volume 130   Number 4   April 2020
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Figure 7. Dexamethasone increases p57Kip2 levels in Epo-induced, BM-derived progenitors, expanding the immature CD105med CFU-E subset. (A) BM
CD34+ progenitors were differentiated in the absence (open circles) or presence (solid circles) of dexamethasone, and total cell numbers on day 14 are presented (n = 5 independent experiments). Data represent the mean ± SEM. *P < 0.05, by 2-tailed Student’s t test. (B) Representative histograms of CD105
expression in BM-derived CD34+ cells differentiated in the absence (black) or presence (red) of dexamethasone on day 4 are shown, and the percentages
of CD105med cells are indicated. (C) Expression of p57Kip2 and GAPDH in purified BM-derived and CB-derived mature CFU-Es, generated in the absence or
presence of dexamethasone, was evaluated by Western blotting (blots from 1 of 3 independent experiments are shown).

led to an increase in p57Kip2 expression that we did not observe
in CB-derived CFU-Es treated with dexamethasone (Figure 7C).
Overall, these data indicate that PB- and BM-derived erythroid
progenitors respond to dexamethasone in a similar manner and
that the phenotypes we observed may be relevant in the clinical
use of dexamethasone for the treatment of red cell disorders.

Discussion

We believe the present study, which focused on identifying the
role of dexamethasone during physiological and pathological
human erythropoiesis, has generated several unique insights.
Our finding that dexamethasone markedly enhanced the erythroid proliferation of CD34+ cells from adult PB but not from
CB was unexpected and very surprising. In this context, it is of
interest that the transition trajectories from BFU-E to CFU-E
differ considerably following erythroid differentiation of
CD34+ cells derived from adult PB and CB (30). Together, these
data strongly suggest that dexamethasone has differential
effects on transitional erythroid progenitor populations that are
regulated by the source of the CD34+ progenitors. Importantly,
these findings are relevant to BM populations, as we found that
CFU-Es from BM-derived CD34+ cells had dexamethasoneinduced responses that were similar to those detected in PBderived CFU-Es (Figure 7).
Although BFU-Es derived from human either PB or CB were not
responsive to dexamethasone, BFU-Es from murine fetal liver have
been shown to be dexamethasone responsive (19). Murine CFU-Es
have also been shown to be specifically dexamethasone responsive
(10), suggesting that dexamethasone-dependent erythroid developmental stages may be species dependent. Collectively, these
previous studies (10, 19), together with the present work, point to
important differences between murine and human systems and,
moreover, demonstrate the importance of the developmental origin of hematopoietic stem and progenitor cells in regulating their
responsiveness to glucocorticoids during erythropoiesis. These
developmental differences as well as steroid resistance in DBA
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may be mediated by epigenetic regulators (40–43), and further
investigations of the mechanisms may offer additional insights into
the heterogeneity of progenitor cell populations. Finally, our data
show the importance of the p57Kip2 cell-cycle inhibitor in mediating dexamethasone effects during human erythroid differentiation
and reveal the critical nature of the p57Kip2 axis in the dexamethasone responsiveness of patients with DBA.
The marked heterogeneity of human erythroid progenitors
has long been recognized (44, 45). Indeed, it has been known for
decades that erythroid progenitors give rise to colonies of different
sizes and morphology in the methylcellulose culture system, which
led to the concept of large, intermediate, and small BFU-E colonies, with the small BFU-E–forming cells further differentiating
into CFU-Es (46). The recent progress of single-cell technologies
has enabled stringent analyses of these varied cell populations with
regard to both steroid sensitivity and cell-fate decisions (12, 47).
Although we previously found that human BFU-Es and CFU-Es
can be immunophenotypically defined on the basis of IL-3R, GPA,
CD34, and CD36 cell-surface markers, this characterization did
not allow us to fully resolve the heterogeneity of human erythroid progenitors. In the present study, we found that the CD71
and CD105 markers allowed for further immunophenotyping,
discriminating subpopulations of erythroid BFU-Es and CFU-Es.
Using this method, we identified a transitional human progenitor
CFU-E population, resulting in the designation of immature and
mature CFU-Es.
Using this optimized immunophenotyping assay, we identified
the immature CFU-E population as the steroid-responsive erythroid progenitor subset, as determined by both proliferation and a
decrease in the percentages of cells in the S phase of the cell cycle.
This cell-cycle phenotype was due to a dexamethasone-mediated
increase in p57Kip2, and under these conditions, differentiation was
delayed, resulting in a paradoxical expansion of this progenitor
subset. We propose that this occurs through the maintenance of
the immature CFU-E population, generating larger numbers of
mature CFU-Es.
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The critical role of p57Kip2 in CFU-Es was shown by shRNA
knockdown, which resulted in an opposite phenotype and an
acceleration of erythroid differentiation that was associated with a
decrease in proliferation. Together with recent work that identifies
a role for cell-cycle status in cell-fate decisions (48), the ensemble
of these data demonstrate a clear link between cell-cycle progression and differentiation of erythroid progenitors.
Importantly, erythroid progenitors from transfusion-dependent patients with DBA harbored altered levels of p57Kip2, and
expression was not sensitive to dexamethasone treatment. Indeed,
the absence of changes in p57Kip2 levels in transfusion-dependent
patients is a proof of concept for the importance of this cell-cycle
regulator in the response to steroids. Notably, though, there was
substantial variability in the phenotype of progenitors from transfusion-dependent patients with DBA that was likely mediated by
other mechanisms. In the future, it will be important to determine
whether steroid responsiveness in patients with DBA is regulated
at the level of a specific subset or subsets of erythroid progenitors
and, furthermore, to assess the role of p57Kip2 levels in these subsets.
Our proteomics data revealed previously unidentified dexamethasone targets that may offer additional insights into how
dexamethasone influences the cell cycle and increases erythroid
proliferation. Of the identified targets, many have been shown to
be involved in cell-cycle regulation including PER1 and NR4A1,
indicating that these proteins may function to negatively regulate
the cell cycle in association with p57Kip2 (31, 49). In this regard, it
is of interest that NR4A1 mediates TGF-β signaling, which is also
aberrant in DBA and could thus be involved in corticosteroid resistance mechanisms (50). Our finding that dexamethasone globally
regulates RNA processing and biosynthetic pathways may also
open additional avenues for studies on the effects of dexamethasone on erythroid progenitors.
The present findings have direct relevance for the clinical use
of corticosteroids for the treatment of hypoproliferative anemias,
most notably DBA. Although corticosteroid use stably increases
red cell mass and induces hematopoietic remission or marked
improvement in many patients with DBA, other patients are not
responsive or cannot continue glucocorticoid treatment because
of adverse side effects. We anticipate that our insights into the
mechanism of action of glucocorticoids on human erythropoiesis,
and specifically on the immature CFU-E subset, will promote the
development of targeted drugs and treatment strategies that will
induce a sustained effect on erythroid progenitors in more patients
with fewer side effects. In summary, we have identified a transitional CFU-E subset, between late BFU-E and mature CFU-E
stages, that is responsive to dexamethasone. These findings contribute to our understanding of erythroid progenitor biology and
will, we believe, lead to the development of new treatment strategies for erythroid disorders.

Methods
Human studies
CD34+ cells were obtained from deidentified control adult PB leukoreduction filters, deidentified CB units, deidentified BM samples, or
phlebotomized patients with DBA. In order to limit sample variability,
blood samples from multiple control PB or CB donors were pooled.
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Patients with DBA were defined as transfusion dependent or steroid responsive on the basis of their clinical need for chronic RBC transfusion or successful management with corticosteroids, respectively.
The 3 patients with DBA presented in Figure 1E were followed
after diagnosis and initial treatment with prednisone. The dose of
prednisone was decreased after the initial response.

Isolation and culturing of CD34+ cells
Mononuclear cells from PB, CB, or BM were separated using Lymphoprep (STEMCELL Technologies), and CD34+ cells were purified with
anti-CD34 microbeads and MACS Columns (Miltenyi Biotec) according
to manufacturer’s protocol. CD34+ cells were cultured at a density of 105
cells/mL in serum-free expansion media as previously described (26),
with a base media of StemSpan SFEM (STEMCELL Technologies) initially supplemented with 100 ng/mL SCF, 10 ng/mL IL-3, 0.5 U/mL Epo,
4 μL/mL lipid mixture 1 (MilliporeSigma), 2 mM l-glutamine, and 200
μg/mL transferrin. Beginning on day 7, the dose of Epo was increased to
3 U/mL, and on day 11, the dose of transferrin was increased to 1 mg/mL.
Dexamethasone (MilliporeSigma) was added to cultures at 100 nM as
indicated, as this dose was found to be optimal (Supplemental Figure 2).
Olomoucine (MilliporeSigma) was added at 1 μM as indicated.
Flow cytometry and cell sorting
Erythroid progenitors were examined using surface markers as previously described (18). Erythroid progenitors were analyzed on day 4 of
differentiation, at which point 105 cells were stained for 15 minutes at
room temperature with an antibody cocktail containing anti–IL-3R phycoerythrin-Cy7 (PE-Cy7), anti–GPA PE, anti–CD34 FITC, anti–CD36
allophycocyanin (APC), anti–CD71 Alexa Fluor 700, and anti–CD105
Brilliant Violet 421 (BD Biosciences; 560826, 555570, 555821, 550956,
560566, and 563920, respectively). BFU-Es were defined as GPA–IL3R–CD34+CD36–, CFU-Es as GPA–IL-3R–CD34–CD36+, and transitional
progenitors as GPA–IL-3R–CD34+CD36+. Dead cells were excluded from
further analysis with 7–aminoactinomycin D (BD Biosciences) staining.
Analysis was performed using a BD Fortessa flow cytometer with FCS
Express 6 and FlowJo 10 software. BFU-Es, CFU-Es, and transitional
progenitors were sorted for downstream experiments using a BD
FACSAria at low pressure with a 100-μm nozzle. Fluorescence minus
1 and isotype controls were used to define the different populations of
progenitor cells and resolve the continuum. Functional assays using
sorted cells in colony-forming assays were performed to further confirm
the identity and purity of the different cell populations.
Colony-forming assays
Sorted erythroid progenitors were seeded onto methylcellulose media
H4230 (STEMCELL Technologies) supplemented with Epo alone at
0.5 U/mL or onto complete methylcellulose media H4435 (STEMCELL
Technologies) at 200 cells/mL. BFU-E and CFU-E colonies were counted
and measured on days 14 and 7 of culturing, respectively. Colony area
was determined by modeling each colony as an ellipse and measuring its
major axis a and minor axis b to calculate the area using the formula area
= πab/4. Dexamethasone (100 nM) was added to cultures as indicated.
Cell-cycle staining
For live cell-cycle staining to examine cell-cycle profile, erythroid progenitors were incubated with 5 mg/mL Hoechst 33342 for 3 hours at
37°C before staining with an antibody cocktail for surface markers.
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Western blot analysis
Cells were lysed in RIPA Lysis and Extraction Buffer (Thermo Fisher
Scientific) with 1:100 protease inhibitor cocktail (MilliporeSigma) on
ice for 10 minutes and then centrifuged at maximum speed for 10 minutes. Supernatants were mixed at 1:1 (vol/vol) with 2× Laemmli Sample Buffer (Bio-Rad) with 0.1 M DTT and boiled for 5 minutes. Samples were then separated with SDS-PAGE for 1.5 hours at 150 V and
transferred onto nitrocellulose membranes for 1 hour at 95 V. Membranes were then blocked with 4% (wt/vol) milk powder and 1% (wt/
vol) BSA in 0.1% Tween-20 (vol/vol) PBST for 3 hours. Membranes
were then incubated with the following primary antibodies overnight
at 4°C: p57Kip2 (BD Biosciences; 556346), p27Kip1 (BD Biosciences;
610241), NR4A1 (BD Biosciences; 554088), GAPDH (Millipore
Sigma; CB1001), and α-globin (Santa Cruz Biotechnology; sc-514378).
Membranes were washed 5 times for 5 minutes with PBST and then
incubated with HRP-conjugated secondary antibodies (Bio-Rad) for 2
hours at room temperature. Membranes were imaged with Pierce ECL
Western Blotting Substrate (Thermo Fisher Scientific) using a ChemiDoc MP Imaging System (Bio-Rad). Western blot images are representative of multiple experiments and were quantified with ImageJ
software (NIH).
Lentivirus transduction
p57Kip2- and p27Kip1-knockdown experiments were each carried out
with 2 lentiviral shRNA-knockdown constructs targeting CDKN1C
and CDKN1B, respectively (clone IDs: NM_000076.2-1451s21c1
and NM_000076.2-1216s21c1 for CDKN1C and NM_004064.3841s21c1 and NM_004064.3-643s21c1 for CDKN1B; Millipore
Sigma). shRNA-knockdown constructs targeting luciferase were
used as controls. After 2 days of culturing in serum-free expansion
media, erythroid progenitors were placed in 10% FBS IMDM with 3
U/mL heparin and 8 μg/mL polybrene. Lentivirus particles were then
added at a MOI of 30 and spinoculated for 2 hours at 1500 g. Cells
were then incubated overnight and placed in serum-free expansion
media. After a 24-hour recovery, lentivirus transduction was positively selected with 1 μg/mL puromycin, which was maintained until
day 11 of culture.
Proteomics profiling
In-solution digestion. CD34+ cell pellets were lysed for 30 minutes at
4°C in 8 M urea, 50 mM Tris-HCl, pH 8.0, 75 mM NaCl, 1 mM EDTA,
2 μg/μL aprotinin (MilliporeSigma), 10 μg/μL leupeptin (Roche), and
1 mM PMSF (MilliporeSigma). Lysates were cleared via centrifugation
at 20,000 g, and protein concentration was determined using a bicinchoninic acid (BCA) protein assay (Pierce, Thermo Fisher Scientific).
Remaining lysis buffer was used to equalize sample concentrations to
the lowest measured concentration before proceeding. Protein reduction was performed with 5 mM DTT for 1 hour at room temperature,
followed by alkylation with 10 mM iodoacetamide for 45 minutes at
room temperature in the dark. Sample volumes were then adjusted
with 50 mM Tris-HCl, pH 8.0, to reduce urea concentration to 2 M
preceding enzymatic digestion. Proteins were digested first with
endoproteinase LysC (Wako Laboratories) for 2 hours at 25°C and then
overnight with sequencing-grade trypsin (Promega) at 25°C, both at
enzyme/substrate ratios of 1:50. Following digestion, samples were
acidified to a concentration of 1% with neat formic acid, and insoluble
peptides and urea were removed via centrifugation at 20,000 g. The
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remaining soluble peptides were desalted using a 100-mg reversephase tC18 SepPak cartridge (Waters). Cartridges were conditioned
with 1 mL 100% MeCN and 1 mL 50% MeCN/0.1% formic acid (FA)
and then equilibrated with 4× 1 mL 0.1% trifluoroacetic acid (TFA).
Samples were loaded onto the cartridge and washed 3 times with 1 mL
0.1% TFA and once with 1 mL 1% FA, and then eluted with 2× 600 μL
50% acetonitrile (MeCN) and 0.1% FA. The peptide concentration of
desalted samples was again estimated with a BCA assay, such that the
proper amount for TMT labeling could be removed, dried in a vacuum
centrifuge, and stored at –80°C.
TMT labeling of peptides. Samples were divided into 2 groups:
PB- and CB-derived cells, and each set was separately labeled with
TMT plex isobaric mass tagging reagents (Thermo Fisher Scientific)
as previously described (51). Each 6-plex contained triplicate samples
of dexamethasone- and DMSO-treated cells. Digested peptides were
resuspended in 50 mM HEPES, pH 8.5, at a concentration of 2.5 mg/
mL. Dried TMT reagent was reconstituted at 20 μg/μL in 100% anhydrous MeCN and added to samples at a 1:1 TMT/peptide mass ratio
(100 μg for PB samples and 70 μg for CB samples due to the limited
amount of material). Labeling was performed for 1 hour at 25°C with
shaking. The TMT reaction was quenched with 5% hydroxylamine
to a final concentration of 0.2% and shaken for 15 minutes at 25°C.
TMT-labeled samples within each plex were then combined, dried to
completion via vacuum centrifugation, reconstituted in 1 mL 0.1% FA,
and desalted with a 100-mg SepPak cartridge as described above.
Basic reverse-phase fractionation. TMT-labeled peptides were
fractionated via offline basic reverse-phase (bRP) chromatography
as previously described (52). Chromatography was performed with a
Zorbax 300 Extend-C18 column (4.6 × 250 mm, 3.5 μm; Agilent Technologies) on an Agilent 1100 HPLC system. Samples were reconstituted in 900 μL bRP solvent A (5 mM ammonium formate, pH 10.0,
in 2% vol/vol MeCN) and injected with this solvent at a flow rate of
1 mL/min. Peptides were separated at the same flow rate with a 96minute gradient, beginning with an initial increase to 16% bRP solvent B (5 mM ammonium formate, pH 10.0, in 90% vol/vol MeCN),
followed by a linear 60-minute gradient to 40% and stepwise ramping to 44% and finally 60% bRP solvent B. A total of 96 fractions were
collected in a row-wise snaking pattern into a Whatman 2-mL 96-well
plate (GE Healthcare) and were then concatenated nonsequentially
into a final 24 fractions for proteomics analysis. The fractions were
dried via vacuum centrifugation.
LC-MS/MS. Dried fractions were reconstituted in 3% MeCN/0.1%
FA to a peptide concentration of 1 μg/μL and analyzed via coupled
Nanoflow LC-MS/MS using a Proxeon Easy-nLC 1000 (Thermo Fisher
Scientific) and a Q-Exactive Plus Series Mass Spectrometer (Thermo
Fisher Scientific). A sample load of 1 μg for each fraction was separated
on a capillary column (36-μm outer diameter × 75-μm inner diameter)
containing an integrated emitter tip and heated to 50°C, followed by
packing to a length of approximately 30 cm with ReproSil-Pur C18-AQ
1.9 μm beads (Maisch GmbH). Chromatography was performed with
a 110-minute gradient consisting of solvent A (3% MeCN/0.1% FA)
and solvent B (90% MeCN/0.1% FA). The gradient profile, described
as minutes/percentage solvent B, was 0:2, 1:6, 85:30, 94:60, 95:90,
100:90, 101:50, and 110:50, with the first 6 steps being performed
at a flow rate of 200 nL/min and the last 2 at a flow rate of 500 nL/
min. Ion acquisition on the Q-Exactive Plus was performed in datadependent mode, acquiring HCD-MS/MS scans at a resolution of
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17,500 on the top-12 most abundant precursor ions in each full MS
scan (70,000 resolution). The automatic gain control (AGC) target
was set to 3 × 106 ions for MS1 and 5 × 104 for MS2, and the maximum
ion time was set to 120 ms for MS2. The collision energy was set to
30, peptide matching was set to “preferred,” isotope exclusion was
enabled, and dynamic exclusion time was set to 20 seconds.
The original mass spectra and the protein sequence database
used for searches have been deposited in the public proteomics
repository MassIVE (http://massive.ucsd.edu) and are accessible at
ftp://massive.ucsd.edu/MSV000084614.
Data analysis. Data were analyzed using Spectrum Mill, version
6.01.202 (Agilent Technologies). In extracting spectra from the raw format for MS/MS searching, spectra from the same precursor or within a
retention time window of ±60 seconds and an m/z range of ±1.4 were
merged. Spectra were filtered to include only those with a precursor
mass range of 750 to 6000 Da and a sequence tag length greater than
0. MS/MS searching was performed against a human UniProt database
(www.uniprot.org). Digestion enzyme conditions were set to “Trypsin allow P” for the search, allowing up to 4 missed cleavages within
a matched peptide. Fixed modifications were carbamidomethylation
of cysteine and TMT6 on the N-terminus and internal lysine. Variable
modifications were oxidized methionine and acetylation of the protein N-terminus. Matching criteria included a 30% minimum matched
peak intensity and a precursor and product mass tolerance of ±20 ppm.
Peptide-level matches were validated if found to be below the 1.0% FDR
threshold and within a precursor charge range of 2 to 6. A second round
of validation was then performed for protein-level matches, requiring
a minimum protein score of 0. Protein-centric information, including
experimental ratios, was then summarized in a table, which was quality filtered for nonhuman contaminants, keratins, and any proteins not
identified by at least 2 fully quantified peptides with 2 ratio counts.

Statistics
All statistical evaluations comparing the different experimental
groups were performed using GraphPad Prism 8 software for unpaired
2-tailed Student’s t test, 2-way ANOVA with Tukey’s post hoc test,
and Kruskal-Wallis test with Dunn’s post hoc analysis with corrections
for multiple comparisons. A P value of less than 0.05 was considered
statistically significant. Raw data and complete, unedited blots corresponding to the additional independent experiments are presented
in Supplemental Figure 7. For proteomics analyses, PB and CB plexes
were analyzed separately, each using biologically paired samples to
compare dexamethasone treatment with a DMSO control. Data were
median normalized and subjected to a 1-sample moderated t test using
an internal R-Shiny package based in the limma R library. Correction
for multiple testing was performed using the Benjamini-Hochberg
FDR method. ssGSEA was performed as previously described (53)
using an R script (available at https://github.com/broadinstitute/
ssGSEA2.0). ssGSEA was performed separately on PB and CB plexes,
1. Danilova N, Gazda HT. Ribosomopathies: how a
common root can cause a tree of pathologies. Dis
Model Mech. 2015;8(9):1013–1026.
2. Vlachos A, Blanc L, Lipton JM. Diamond Blackfan
anemia: a model for the translational approach to
understanding human disease. Expert Rev Hematol. 2014;7(3):359–372.

using the log2-transformed ratios of dexamethasone/control as input.
Parameters were set as follows: sample.norm.type = “rank”, weight =
0.75, statistic = “area.under.RES”, output.score.type = “NES”, nperm
= 1e3, min.overlap = 10, correl.type = “z.score”, par = T, spare.cores = 1.
The heatmap in Figure 3F was generated using the average of triplicate
enrichment scores, ranked to create a list of top-10 and bottom-10,
eliminating redundant rows. It should be noted that the TMT plex
design used limits direct quantitative comparisons between PB and
CB samples, as the stochastic sampling of spectra on the mass spectrometer can lead to technical differences in the proteins identified in
different plexes that are not necessarily driven by biological causes.
Therefore, the observed differences between PB and CB samples were
validated in follow-up experiments.
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